GlaxoSmithKline Pharmaceuticals Limited
Bombay Stock ExchangeTotal Valuation
GlaxoSmithKline Pharmaceuticals Limited carries a market capitalization of 405.96B, placing it among publicly traded companies globally. Its enterprise value stands at 573.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 405.96B |
| Enterprise Value | 573.67B |
Valuation Ratios
GlaxoSmithKline Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 60.37.
| PE Ratio | 60.37 |
| PS Ratio | 15.34 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, GlaxoSmithKline Pharmaceuticals Limited trades at an EV/EBITDA multiple of 50.67 and an EV/FCF ratio of 57,238.63. The EV/Sales ratio of 15.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 50.67 provides insight into valuation relative to core operating earnings.
| EV / Sales | 15.34 |
| EV / EBITDA | 50.67 |
| EV / EBIT | 50.67 |
| EV / FCF | 57,238.63 |
Financial Position
GlaxoSmithKline Pharmaceuticals Limited maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.39, indicating moderate leverage, while an interest coverage ratio of 832.44 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.45 |
| Quick Ratio | 2.52 |
| Debt / Equity | 1.39 |
| Debt / EBITDA | N/A |
| Interest Coverage | 832.44 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 441.10 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, GlaxoSmithKline Pharmaceuticals Limited has paid 3.39B in income taxes, reflecting an effective tax rate of 26.31.
| Income Tax | 3.39B |
| Effective Tax Rate | 26.31 |
Stock Price Statistics
GlaxoSmithKline Pharmaceuticals Limited's stock has declined approximately -27.06108% over the past 52 weeks. The 50-day moving average sits at 2,461.91, while the 200-day moving average is 2,797.62.
| Beta (5Y) | N/A |
| 52-Week Price Change | -27.06108% |
| 50-Day Moving Average | 2,461.91 |
| 200-Day Moving Average | 2,797.62 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, GlaxoSmithKline Pharmaceuticals Limited generated 37.40B in revenue and converted that into 9.50B in net income, yielding earnings per share of 56.10. EBITDA reached 11.32B, while operating income came in at 11.32B.
| Revenue | 37.40B |
| Gross Profit | 23.56B |
| Operating Income | 11.32B |
| Pretax Income | 12.89B |
| Net Income | 9.50B |
| EBITDA | 11.32B |
| EBIT | 11.32B |
| Earnings Per Share (EPS) | 56.10 |
Margins
GlaxoSmithKline Pharmaceuticals Limited operates with a gross margin of 63.01, reflecting its pricing power and cost economics. The operating margin of 30.27 and net profit margin of 25.41 provide insight into operational efficiency.
| Gross Margin | 63.01 |
| Operating Margin | 30.27 |
| Pretax Margin | 34.48 |
| Profit Margin | 25.41 |
| EBITDA Margin | 30.27 |
Stock Splits
GlaxoSmithKline Pharmaceuticals Limited's most recent stock split took place on September 11, 2018 with a 1:2 split ratio.
| Last Split Date | 9/11/2018 |
| Split Ratio | 1:2 |
Scores
GlaxoSmithKline Pharmaceuticals Limited posts an Altman Z-Score of 31.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 31.86 |